Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02038764 · ClinicalTrials.gov registry record · Phase 1

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

A Phase 1 study of Diabetes Mellitus, Type 1, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
20
Study locations

NCT02038764 is a Phase 1 study of Diabetes Mellitus, Type 1 that has completed, run by Pfizer. The registered enrollment target is 37 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02038764, a Phase 1 study of Diabetes Mellitus, Type 1, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.

Conditions Studied

Diabetes Mellitus, Type 1

Interventions

  • DRUG Placebo
  • BIOLOGICAL PF-06342674 Dose A
  • BIOLOGICAL PF-06342674 Dose B
  • BIOLOGICAL PF-06342674 Dose C
  • BIOLOGICAL PF-06342674 Dose D

Study Locations (20)

Illinois

  • Duchossois Center for Advanced Medicine - Chicago
  • The University of Chicago Medical Center - Chicago
  • University of Chicago Clinical Resource Center - Chicago
  • University of Chicago Medical Center - Chicago

California

  • VA San Diego Healthcare System (Drug Shipment) - San Diego
  • Veterans Administration San Diego Healthcare System - San Diego
  • University of California, San Francisco - San Francisco

Connecticut

  • Yale School of Medicine - New Haven
  • Yale New Haven Hospital - Investigational Drug Services - New Haven
  • Yale University School of Medicine - New Haven

Missouri

  • Barnes- Jewish HOSP Att: Kathryn Vehe - St Louis
  • Washington University - Center for Advanced Medicine - St Louis
  • Washington University - St Louis

Massachusetts

  • Umass Memorial Medical Center - Worcester
  • University of Massachusetts Medical School - Worcester

Minnesota

  • University Of Minnesota Fairview Pharmacy Services - Minneapolis
  • University Of Minnesota Medical School - Minneapolis

Colorado

  • Barbara Davis Center - Aurora

Georgia

  • Atlanta Diabetes Associates - Atlanta

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2014-06-04
Est. Completion 2016-09-13
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02038764

The ClinicalTrials.gov registry entry for NCT02038764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT02038764 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02038764 about?

NCT02038764 is a clinical study titled "A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.

What is the current status of trial NCT02038764?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2014-06-04. Estimated completion is 2016-09-13.

What conditions does trial NCT02038764 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT02038764?

The interventions under investigation include: Placebo (DRUG), PF-06342674 Dose A (BIOLOGICAL), PF-06342674 Dose B (BIOLOGICAL), PF-06342674 Dose C (BIOLOGICAL), PF-06342674 Dose D (BIOLOGICAL).

Who is sponsoring clinical trial NCT02038764?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02038764 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 1

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.